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Introduction: Breast cancer remains a significant scientific, clinical and societal challenge. This gap analysis has
reviewed and critically assessed enduring issues and new challenges emerging from recent research, and proposes
strategies for translating solutions into practice.
Methods: More than 100 internationally recognised specialist breast cancer scientists, clinicians and healthcare
professionals collaborated to address nine thematic areas: genetics, epigenetics and epidemiology; molecular
pathology and cell biology; hormonal influences and endocrine therapy; imaging, detection and screening; current/
novel therapies and biomarkers; drug resistance; metastasis, angiogenesis, circulating tumour cells, cancer ‘stem’
cells; risk and prevention; living with and managing breast cancer and its treatment. The groups developed
summary papers through an iterative process which, following further appraisal from experts and patients, were
melded into this summary account.
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Results: The 10 major gaps identified were: (1) understanding the functions and contextual interactions of genetic
and epigenetic changes in normal breast development and during malignant transformation; (2) how to implement
sustainable lifestyle changes (diet, exercise and weight) and chemopreventive strategies; (3) the need for tailored
screening approaches including clinically actionable tests; (4) enhancing knowledge of molecular drivers behind
breast cancer subtypes, progression and metastasis; (5) understanding the molecular mechanisms of tumour
heterogeneity, dormancy, de novo or acquired resistance and how to target key nodes in these dynamic processes;
(6) developing validated markers for chemosensitivity and radiosensitivity; (7) understanding the optimal duration,
sequencing and rational combinations of treatment for improved personalised therapy; (8) validating multimodality
imaging biomarkers for minimally invasive diagnosis and monitoring of responses in primary and metastatic
disease; (9) developing interventions and support to improve the survivorship experience; (10) a continuing need
for clinical material for translational research derived from normal breast, blood, primary, relapsed, metastatic and
drug-resistant cancers with expert bioinformatics support to maximise its utility. The proposed infrastructural
enablers include enhanced resources to support clinically relevant in vitro and in vivo tumour models; improved
access to appropriate, fully annotated clinical samples; extended biomarker discovery, validation and
standardisation; and facilitated cross-discipline working.
Conclusions: With resources to conduct further high-quality targeted research focusing on the gaps identified,
increased knowledge translating into improved clinical care should be achievable within five years.Introduction
Globally, breast cancer is the most frequently diag-
nosed cancer in women, with an estimated 1.38 million
new cases per year. Fifty thousand cases in women and
400 in men are recorded each year in the UK alone.
There are 458,000 deaths per year from breast cancer
worldwide making it the most common cause of female
cancer death in both the developed and developing
world [1].
In the UK, the age-standardised incidence of breast
cancer in women has increased by 6% over the last dec-
ade, between 1999 to 2001 and 2008 to 2010 [2]. It is es-
timated that around 550,000-570,000 people are living
with or after a diagnosis of breast cancer in the UK [3]
and, based on current projections, this figure is expected
to triple by 2040 due to an ageing population and con-
tinued improvements in survival [4]. Recent research
indicates that the annual cost of breast cancer to the UK
economy is £1.5bn, with just over a third of that cost
(£0.6bn) from healthcare alone [5]. Yet the annual spend
on breast cancer research by partners of the National
Cancer Research Institute has reduced in recent years
despite the level of cancer research spend being gener-
ally maintained [6].
In 2006, the charity Breast Cancer Campaign facili-
tated a meeting of leading breast cancer experts in the
United Kingdom to explore which gaps in research, if
filled, would make the most impact on patient benefit.
The subsequent paper [7] has helped shape the direction
of breast cancer research since that time. One overarch-
ing need identified was the ‘lack of access to appropriate
and annotated clinical material’, which directly led to theformation of the UK’s first multi-centre, breast-specific
tissue bank [8].
This new gap analysis represents an expanded, evidence-
based follow-on developed collaboratively by clinicians,
scientists and healthcare professionals. The aim is to en-
sure that the roadmap for breast cancer research re-
mains a relevant, consensual and authoritative resource
to signpost future needs. It builds upon the previous
gap analysis by briefly reviewing the current status of
key areas, critically assessing remaining issues and new
challenges emerging from recent research findings and
proposes strategies to aid their translation into practice.
Whilst a survey of progress during the last five years is
not the intention of this article, the preparatory detailed
discussions and data analysis could provide the basis for
such a retrospective review.
Methods
During 2012, Breast Cancer Campaign facilitated a series
of workshops, each covering a specialty area of breast can-
cer (Figure 1). These working groups covered genetics,
epigenetics and epidemiology; molecular pathology and
cell biology; hormonal influences and endocrine therapy;
imaging, detection and screening; current and novel ther-
apies and associated biomarkers; drug resistance; invasion,
metastasis, angiogenesis, circulating tumour cells, cancer
‘stem’ cells; breast cancer risk and prevention; living with
and managing breast cancer and its treatment. Working
group leaders and their multidisciplinary teams (compris-
ing a representative cross-section of breast cancer clini-
cians, scientists, and healthcare professionals) participated
in iterative cycles of presentation and discussion, offering
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Figure 1 Gap analysis methodology. The flow chart illustrates the concept, processes and procedures devised to generate the gap
analysis review.
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reviewed literature. Summary reports were prepared by
each group, collated, condensed and edited into a draft,
which was critically appraised by an external Executive
Advisory Board of international experts. This position
paper highlights the key gaps in breast cancer research
that were identified, together with detailed recommen-
dations for action.
Results
Genetics, epigenetics and epidemiology
Current status
Genetic predisposition Our knowledge of the herit-
ability of breast cancer has increased significantly since
2007. Known breast cancer genes (BRCA1, BRCA2,
CHEK2, ATM, PALB2, BRIP1, TP53, PTEN, CDH1 andSTK11) make up 25 to 30% of the heritability [9].
Genome-wide association studies (GWAS) and the recent
international collaborative analyses have confirmed 77
common polymorphisms individually associated with
breast cancer risk, which add a further 14% [9-11].
Evidence from an Illumina collaborative oncological gene-
environment study (iCOGS) experiment suggests that
further single nucleotide polymorphisms (SNPs) may con-
tribute at least 14% to the heritability, leaving only approxi-
mately 50% as ‘missing heritability’ (Figure 2).
If we assume the risk estimates for polygenic markers
are log additive, the cumulative risk associated with these
SNPs has a median of 9% to age 80 (95% confidence inter-
vals 5 to 15%). In the familial setting, we have learnt that
common genetic SNPs can modify the risk associated with
BRCA2, which may be relevant when considering risk-
reducing surgery [12,13].
2007
2013
Figure 2 Familial cancer genetics. The proportion of the familial component of breast cancers that can be ascribed to specific genetic defects.
The difference between June 2007 and 2013 shows the impact of genome-wide association studies (GWAS) that have now identified 77
common low-risk SNPs. Courtesy of Professor Douglas Easton (University of Cambridge). Reprinted by permission from Macmillan Publishers Ltd:
Nature Genetics (45,345-348), copyright 2013.
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of the function of BRCA1 and BRCA2 in relation to DNA
repair and therapeutic responses. For example, BRCA2
functions in RAD51 loading and BRCA1 in countering
53BP1-mediated blocking of homologous recombinational
(HR)-DNA repair; hence poly (ADP-ribose) polymerase
(PARP) inhibitors have been developed and trialled against
BRCA-driven cancers [14]. Several additional genes asso-
ciated with breast cancer risk are part of the BRCA net-
work and there is a clear relationship with the Fanconi
pathway [9]. Genes in this network point to reduced
HR-DNA repair as the mechanism underlying cancer
susceptibility, although the precise functions of associ-
ated signalling proteins (for example PTEN, CHK2,
ATM and N-terminal BRCA1) that relate to cancer devel-
opment are unknown. Gene interactions of some higher
risk alleles are recognised to be sub-multiplicative, whereas
low risk alleles are log-additive [15]. Some susceptibility
SNPs may function at the level of chromatin remodelling/
enhancer activity related to nearby gene expression.
Epigenetics Epigenetic alterations are frequent and
cancer-specific methylation in circulating tumour (ct)DNA
in serum can be used as an early detection biomarker, or as
a prognostic indicator [16,17]. The recent ENCODE studyprovided a wide-ranging analysis of epigenetic marks on a
small fraction of the genome [18]. The first candidate gene
epigenetic risk factor that could usefully be included in
breast cancer risk models (once fully validated) has been
identified [19]. Epigenetic factors also provide molecular
measures of long-term exposure to potentially oncogenic
agents. Epigenetic alterations are reversible; preclinical
and recent clinical testing of epigenetic-targeted therap-
ies such as etinostat (a DNA methylation inhibitor) and
vorinostat (a histone deacetylase inhibitor) indicate that
such drugs may prove effective in combination with
other therapies [20,21].
Psychosocial considerations Predictive genetic testing
for breast cancer predisposition genes can increase dis-
tress in the short term (which reduces over time) for
those identified as gene carriers, whilst non-carriers re-
port lower levels of concern following genetic testing
[22]. A number of interventions have now been devel-
oped and tested to support the genetic testing process
and have been shown to reduce distress, improve the
accuracy of the perceived risk of breast cancer, and in-
crease knowledge about breast cancer and genetics [23].
Examples introduced since the last gap analysis include
education using tailored information technology to
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tions to support women’s decisions about whether or
not to have genetic testing [25] and support for gene
carriers thus identified [12].
What are the key gaps in our knowledge and how might
they be filled?
Moderate risk alleles Remaining ‘moderate risk’ alleles
will be found within the short term by exome sequencing
and extended GWAS studies will identify additional lower
risk alleles. If up to 28% of the risk from known SNPs
could be explained, while the median of the risk distribu-
tion changes little, confidence limits would change dra-
matically, such that the women in the top 5% at risk
would have >15% lifetime risk, compared with <3% life-
time risk at the lower end. A prospective analysis will be
required to show that genetic risk assessment can predict
risk when combined with mammographic screening.
We need to determine if or how common SNPs modify
the contributions of BRCA1-associated and moderate
risk genes (such as CHEK2, ATM) and whether this is
influenced by oestrogen levels or risk management using,
for example, lifestyle or chemopreventive approaches.
Functional implications of unclassified variants in
BRCA1/BRCA2, fine-mapping of risk-associated variants
(from GWAS) and understanding the functional impact of
the more common SNPs such as TOX3 and the role of
FOXA1 remain to be determined. Similarly, deconvoluting
the functional interactions between susceptibility genes
and known breast cancer-associated proteins require sys-
tems biology approaches. Can we achieve a clear clinical
use of the knowledge gained by GWAS, SNP and BRCA
studies by validation of risk models incorporating SNPs
and moderate risk alleles (in particular in the familial set-
ting) to improve risk management? A randomised trial for
population screening with mammography stratified on in-
dividual genetic risk estimates (combined with other key
risk factors) is warranted.
BRCA1 and 2 A scheme to define categories of risk for
variants in BRCA (and other) cancer genes is needed to
provide specific clinical recommendations. BRCA vari-
ants of uncertain significance occur in approximately 5%
of all genetic tests for BRCA1/BRCA2 mutations [26]. A
range of in silico and functional assays is available to
provide evidence for or against a genetic variant being
pathogenic. A calculation combining all lines of evidence
can estimate the posterior probability that a particular
gene variant is predisposing to disease. The expression of
breast cancer genes in normal breast tissue and pathways
that may underlie cancer risk (such as DNA damage re-
sponse) could be used to identify tractable markers and to
direct treatment choice. Additional BRCA-deficient humantumour cell lines and animal models of breast cancer are
required.
Epigenetics There is a gap in our understanding of cause
or consequence between epigenetic traits and gene tran-
scription. Translational studies are needed to investigate
epigenetic patterns in clinical material and from clinical
trials to identify and validate prognostic markers. The ex-
tent to which epigenetic markers can be incorporated into
risk models alongside genetic and lifestyle factors is not
yet known. Understanding how cancer risk factors impact
on the epigenome and whether this provides a mechanism
for increased risk associated with those exposures is
poorly understood.
Psychosocial considerations Further research is needed
to support informed decision making about risk man-
agement options and to assess the psychosocial implica-
tions of changing behaviour and anxiety about cancer
[27]. Interventions to support discussions with those
newly diagnosed with breast cancer are being developed
to improve understanding of risk to individuals and their
families [28]. Interventions are also required to support
conversations within the family about genetic risk and
its implications, given that the onus is often on the pa-
tient [29]. Research involving women at increased gen-
etic risk for breast cancer should assess the psychosocial
impact on partners and the implications for their rela-
tionships [30]. Evidence from this research needs to in-
form services and direct resources to support those at
increased risk of breast cancer.
Risk and prevention
Current status
Risk estimation We know little about the exact cause(s)
of the majority of breast cancers. The major challenge
for prevention is to identify women at risk as precisely
as possible and then to apply measures such as chemo-
prevention and lifestyle changes. Current models can
predict probable numbers of breast cancer cases in spe-
cific risk factor strata, but have modest discriminatory
accuracy at the individual level [31]. The publication of
more than 70 common genetic susceptibility factors via
large-scale collaborative efforts [10,32] and the realisa-
tion that mammographic density is a major risk factor is
important, but the major gap in our knowledge is how
to incorporate these factors into our current risk predic-
tion models [33].
Automated methods for estimation of mammographic
density require further evaluation for its potential use as
a biomarker for risk stratification in screening and
changes in density as a biomarker of responsiveness to
preventive approaches. Studies of chest irradiation for
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the importance of exposure to radiation during pu-
berty [34,35].
There is a need to assess the value of several new ap-
proaches to discovering biomarkers including adductomics,
transcriptomics, metabolomics [36] and epigenomics and
to determine how well-established measurements (for
example oestrogen levels) can be incorporated into risk
models [37].
Chemoprevention An overview of all trials of selective
oestrogen receptor modulators (SERMs) as chemopre-
ventive agents indicates that risk is reduced by 38% for
up to 10 years from the start of five years’ treatment
[38]. An issue is predicting those women who will bene-
fit from SERM treatment. Lasofoxifene appears to be the
most active SERM and its further development is desir-
able [39]. In postmenopausal women, the MA P3 trial
indicated that exemestane reduced risk by 65% after 35
months median follow-up [40] requiring confirmation
with additional aromatase inhibitor (AI) prevention
studies. The value of low-dose tamoxifen and fenretinide
also needs to be established [41]. Since SERMs and AIs
reduce only oestrogen receptor positive (ER+ve) disease,
there is a need for agents to prevent ER negative (ER-ve)
disease, to distinguish between ER- and progesterone re-
ceptor (PR)-related disease [42] and to develop better
animal models [43]. There is a need to confirm that
oestrogen-only hormone replacement therapy (HRT) re-
duces risk whereas combined HRT increases risk in the
Women’s Health Initiative (WHI) trials and to establish
the mechanism of this dichotomy [44,45].
Lifestyle changes Most studies related to breast cancer
risk and lifestyles are observational. Favourable changes
in lifestyle including reduction of calorie excess, increas-
ing exercise, reducing alcohol intake and less environ-
mental exposures to disturbance of circadian rhythm
could reduce breast cancer by one third [46-49]. Com-
municating the potential benefits of lifestyle change,
identifying teachable moments and using health services
to endorse lifestyle change for prevention will require
additional studies to determine why health beliefs trans-
late poorly into action [50].
Weight Marked adult weight gain in premenopausal
women is associated with a doubling of risk of postmen-
opausal breast cancer compared with no or little weight
gain [51]. Conversely, weight loss of 3kg or more is associ-
ated with a 25 to 40% reduction of cancer in older women
compared with those who continue to gain weight. [52-54].
It is not clear whether to focus on all overweight women,
those with gynoid or abdominal obesity or those with
metabolic syndrome. Weight gain after surgery for breastcancer increases risk of relapse [55]; there is a need for
further randomised trials to determine whether reducing
weight in the overweight, or preventing weight gain after
surgery prevents relapse. Weight management strategies
seeking efficacy in the long term may be particularly diffi-
cult to sustain.
Diet The effect of individual components of diet is con-
troversial. The risk of ER-ve tumours may be reduced by
high vegetable intake [56] while lowering fat intake may
reduce both breast cancer risk and relapse after surgery.
However, two of the three randomised trials of lower fat
intake are confounded by concomitant weight loss
[57,58] and the one study without weight loss showed
no effect of reduction of fat intake on breast cancer re-
lapse after surgery [59].
Exercise There is evidence for breast cancer prevention
with habitual exercise [60]. Observational evidence
shows that a physically active lifestyle after cancer treat-
ment prevents relapse and reduces the risk of all-cause
mortality [61]. The optimal exercise regime and timing
are uncertain and randomised trials are required to as-
sess the preventive benefits. There is a need to under-
stand the mechanism of the apparent beneficial effects
of caloric restriction and exercise.
Effective and sustainable lifestyle changes (diet, exercise
and weight) need to be agreed and effective routes to initi-
ation and maintenance identified. Further work needs to
be undertaken in chemoprevention strategies and adher-
ence to effective agents.
What are the key gaps in our knowledge and how might
they be filled?
Risk estimation Prospective cohort studies are needed
to develop and validate risk models, which may need to
incorporate polygenic risks, mammographic density and
measures of body composition. Risks may be refined by
the discovery and validation of novel biomarkers such as
epigenetic markers [19] and prospective validation of
known markers such as serum oestrogen [62,63]. Effect-
iveness and cost-effectiveness, analyses to evaluate pos-
sible personalised screening and prevention programmes
[64] and pilot studies to evaluate delivery options
followed by large randomised trials are required. Poly-
genic and other biomarkers should be used to distin-
guish between the development of ER+ve, ER+ve/PR+ve
and ER–ve cancers.
Many breast cancers arise in women without apparent
risk factors; current studies suggest that polygenic risk
factors and mammographic density add only a little to the
Gail model [65]. Precision is required using polygenic
approaches to decide whether or not to give preventive
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women with a 10-year risk above 5%. Taking this at-risk
group and increasing the frequency of screening would be
of some benefit, but more effective risk-adapted screening
will depend upon a better definition of risk.
Screening Further improvement and cost-effectiveness
of the NHS breast cancer screening programme could
include tomography, ultrasound and automated methods
for the measurement of volumetric mammographic
density (using software programs such as Quantra or
Volpara) and automatically using these for risk stratifica-
tion to adapt screening interval to risk. Experimentally,
there are now opportunities for determining whether
high breast density alters the response of breast epithe-
lial cells to DNA damage or oncogene activation. This
may provide prognostic value if we can define novel bio-
markers to distinguish which women with high mammo-
graphic density will develop cancer [66,67].
Chemoprevention Uptake of tamoxifen and raloxifene
is variable and optimal methods need to be developed to
explain risk, the benefit/risk ratio of treatment and to
identify women who will benefit. The benefit from tam-
oxifen may be determined by changes in mammographic
density [68] but needs confirmation. Identification of
women who could develop ER-ve tumours should be-
come possible (for example by polygenic scores). Work
is required to corroborate the efficacy of lasofoxifene;
the use of AIs in the preventive setting should be clari-
fied by the International Breast Cancer Intervention
Study II (IBIS II) trial, while the use of low-dose tamoxi-
fen and retinoids also await trial results. Further studies
are required to develop new preventive agents; those
which might be pursued further include rexinoids,
omega 3 fatty acids, sulphorophane, antiprogestins and
insulin-like growth factor 1 (IGF1) inhibitors [409].
The widespread introduction of preventive agents de-
pends upon efficient methods for identifying risk and ef-
fective counselling. Neither has been widely taken up,
particularly in postmenopausal women, but the recently
published NICE guidelines may signal a change for the
use of tamoxifen in chemoprevention. Identification within
screening programmes may be a valid approach [64]. How-
ever, since trials of chemoprevention require long duration
and are costly, the development of biomarkers as indica-
tors of effectiveness and their acceptance by regulatory
agencies is attractive.
Lifestyle change for breast cancer prevention A pre-
cise definition of interventions for diet and exercise and the
relative importance for reduction of ER+ve or ER-ve breast
cancer is unclear. The effect of caloric restriction by age
and the duration of interventions remain unknown as dothe underlying mechanisms of action. Identifying successful
methods to translate prevention evidence into public health
policy including effective behaviour change programmes
and convincing clinicians to change practice in favour of
prevention are required. Most evidence for lifestyle change
is observational and confirmatory data from prospective
randomised controlled trials (RCTs) with long-term
follow-up and clinical endpoints may be needed. A breast
cancer prevention trial using exercise would require a
sample size of 25,000 to 35,000 and an eight to ten-year
follow-up to observe a 20 to 25% decrease in risk for a
moderate-to-vigorous physical activity programme. Such a
large-scale study is not currently possible so the focus has
been on a RCT of exercise in breast cancer patients to de-
termine how exercise influences survival. The AMBER co-
hort study in 1,500 breast cancer patients measures
physical activity, fitness and other indicators to determine
exactly how physical activity influences survival [69].
Nevertheless, the beneficial effects demonstrated in
randomised trials to prevent diabetes and cardiovascular
disease need to be balanced against the enormous size and
cost that would be required for such trials in breast cancer.
For secondary prevention of disease recurrence after sur-
gery, trials are due to report on caloric restriction and exer-
cise in 2014 and 2018 [70,71].
There are teachable moments within the breast screen-
ing programmes for links to prevention through changes
in lifestyle [50,64]. Reduction in alcohol consumption
using community/class/cultural approaches, analogous to
those for smoking, needs to be explored using social mar-
keting approaches within a research context. It is likely
that energy restriction and exercise will not be a complete
answer to prevention and efforts should be made to design
lifestyle prevention trials with and without energy restric-
tion mimetic agents such as mTOR inhibitors, resveratrol,
and metformin. mTOR inhibitors such as everolimus
(RAD001) are effective in advanced breast cancer [72] al-
though toxicities will prevent its use as a preventive agent;
rapamycin in animal models reduces tumour incidence
and increases longevity [73]. There is a need to translate
these important findings into the clinic, perhaps by low
dose or intermittent regimens to avoid toxicity [74].
Metformin is in clinical trial as an adjuvant for breast
cancer treatment and demonstration of effectiveness in
this situation could lead to assessment for prevention in-
cluding in prediabetic populations [75].
Molecular pathology
Current status
Breast cancer classification and issues of heterogeneity
During the last five years several high-profile studies have
significantly advanced the molecular subclassification of
breast cancer (reviewed in [76] and [77]). Intratumoral
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cancer is well documented. It is likely that both genetic
and epigenetic instability, combined with microenviron-
mental and therapy-induced selective pressures lead to
clonal evolution, which continues during metastatic
progression. However, whether heterogeneity arises from
cancer stem cell plasticity and a hierarchy of aberrant
differentiation or stochastic events is a moot point
(Figure 3). Genomic studies have been used to develop
both prognostic biomarkers and to identify biomarkers
to predict response to therapy. Nevertheless, ‘driver’
genetic changes in breast cancer will need to be fil-
tered from the background, clinically inconsequential
changes [78].
Exploring the diversity and inter-tumour heterogeneity
of breast cancer has led to the development of a novelPatient 1 Patient 2
Cancer ‘stem’ cell Primary tumour
Normal cell Genetic & Clonal evolution
A
B
epigenetic
events
Figure 3 Tumour heterogeneity. (A) Recent molecular and genetic profi
arise through genomic instability (leading to mutations), epigenetic events
proposes that tumour-initiating cells are pluripotent and can thus give rise
be due to stochastic events. Temporal heterogeneity can be exacerbated b
eliminated whilst others expand). The significant molecular/genetic differen
primary and metastatic tumours (and potentially between cancer cells that
reliability of primary tumour biopsies for diagnosis, seeking biomarkers for
substantial inter-tumour heterogeneity. (B) shows images of two patients w
biochemical parameters. Four years later, one patient is clear of disease, wh
between-patient heterogeneity in terms of response to therapy (clinical im
Rut Klinger and Dr Donal Brennan (UCD Conway Institute).classification that integrates genomic and transcriptomic
information to classify 10 subtypes with distinct clinical
outcomes [79]. Triple-negative breast cancer (TNBC) in
particular is now recognised to demonstrate heterogeneity
at the molecular, pathological and clinical levels. [80]. Such
analyses, together with advanced next-generation sequen-
cing have significant implications for improved under-
standing of basic tumour biology and will potentially
enable the identification of new molecular targets for
personalised treatment plans [81,82] Additionally, identifi-
cation of non-coding RNAs is showing potential in diag-
nosis, prognosis and therapy [83].
Microenvironmental influences and tumour - host in-
teractions Breast development is critically reliant upon
cell polarity [84], choreographed cell death pathways andTherapy Relapse Metastasis
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ling has demonstrated significant intratumoural heterogeneity that can
and/or microenvironmental influences. The stem cell hypothesis
to progeny of multiple phenotypes; alternatively heterogeneity could
y therapy (theoretically due to clonal evolution as some clones are
ces between cells in different areas within individual cancers, between
successfully colonise different organs) have implications for the
treatment planning and responses to therapy. In addition, there is
ho presented with breast cancers of identical histological type and
ile the other has evidence of multiple distant metastases, illustrative of
ages kindly provided by Professor William Gallagher, with thanks to Dr
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cesses which when deregulated are implicated in onco-
genesis and tumour progression [85-87]. The tumour
microenvironment, comprising a community of both
malignant and non-malignant cells, significantly influ-
ences breast cancer cell behaviour [88,89]. Recently,
progress has been made in understanding the bidirectional
interplay between tumours and surrounding stromal cells/
extracellular matrix (ECM), which can potentiate resist-
ance to targeted therapies including endocrine therapy
[90,91]. Consequently, components of the tumour micro-
environment may represent targets for therapeutic inter-
vention alongside the tumour to improve response to
treatment [92].
Hypoxia reflects dynamic microenvironmental condi-
tions in solid tumours, limits responses to radiotherapy
[93] and some chemotherapeutic and anti-endocrine
agents [94,95], drives genomic instability and is generally
associated with progression to invasive/metastatic dis-
ease [96,97]. Tumour-stromal interactions change under
hypoxic conditions to promote tumour progression via
the activity of enzymes such as LOX [98], angiogenic
factors and infiltrating macrophages [99,100]. A stem-
like breast cancer cell subpopulation with an epithelial-
mesenchymal transition (EMT) phenotype is expanded
during repetitive hypoxia/reoxygenation cycles [101].
Hypoxia also contributes to cancer stem cell plasticityPhysiological 
Environment
Physical 
Environment
Figure 4 Microenvironmental influences on breast cancer. Breast cance
levels from epigenetic effects on gene expression (for example methylation) t
inflammatory and angiogenic components, hypoxia, host endocrinological an
environment in which we live.and niche formation [102] potentially explaining the re-
lationship between hypoxia and chemotherapy resistance
[103]. Finally, at the physiological level, host metabolic,
inflammatory and immunological factors can impact on
cancer development and progression, and these pro-
cesses are further modified by the physical environments
in which we live (Figure 4).
What are the key gaps in our knowledge and how might
these be filled?
Normal breast development and the origins of cancer
It is not known how many breast epithelial cell subpopula-
tions function as stem cells (capable of self-renewal) or
progenitor cells (which proliferate expansively) [104-106].
Clearer understanding of cell lineages, changes in tran-
scription factor expression during breast development and
definition of the nature of stem and progenitor cells is fun-
damental to delineating relationships between normal and
malignant cells.
Current cancer stem cell (CSC) assays have limita-
tions: dormant cells cannot be detected and cell subpop-
ulations that give rise to clones in vivo may not be active
in ‘mammosphere’ cultures. There is no clear consensus
on markers that define functional breast CSC in mouse
and human. Indeed, they may not represent a fixed sub-
population, but instead exist in specific niches in flexibleMetastatic niches
T GC
DNA
Tumour-stroma
host cells
CH3
CH3CH3
r biology, progression and response to therapy is influenced at many
hrough soluble and cell-mediated stromal interactions, intratumoural
d immunological status through to exposure to multiple agents in the
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on interactions between them as well as external select-
ive pressures [107-109]. Understanding this plasticity
[110] and its therapeutic implications are key areas for
future investigation.
Breast cancer subtypes: genomics and bioinformatics
Several large-scale, cross-sectional, integrated molecular
studies have established comprehensive molecular por-
traits of invasive primary breast cancers [111-114]. The
International Cancer Genome Consortium (ICGC), The
Cancer Genome Atlas (TCGA) and individual studies
have released sequence data; however, gaining access to
and interrogating this information requires expert bio-
informatic collaborations. Relating these advances in
genomic knowledge to improving clinical care has yet to
be achieved. Knowledge of genetic, epigenetic and host
factors underpinning distinct subtypes of breast cancer
(plus their associated aberrant signalling pathways) and
predictive biomarkers will be essential in targeting new
therapeutic agents to the right patients.
For ductal carcinoma in situ (DCIS), an increased un-
derstanding is required of molecular markers of prognosis,
thus providing key information to avoid overtreatment.
We need to know which DCIS lesions will recur if ad-
equate surgery is performed with wide, clear margins.
Biological markers of DCIS should aim at defining
which lesions are likely to progress, in order to avoid
radiotherapy or even surgery if the risk of invasive cancer
is sufficiently remote [115]. Markers for response to radio-
therapy or endocrine therapy and the need for these ther-
apies (particularly in low-risk patients) remain unclear.
Tumour microenvironment and stromal influences
Paget’s venerable ‘seed and soil’ analogy - recognising
that tumour-initiating cells require a permissive host en-
vironment to thrive - is beginning to be deciphered at
the molecular level. [42]. The composition and biophys-
ical characteristics of the breast matrisome [116] and
how it controls different stages of gland development
and in early breast cancer requires definition. It is im-
portant to identify the transcription factors that define
luminal and myoepithelial cells and to understand
whether additional microenvironmental factors such as
the ECM and fibroblast growth factor (FGF), Notch or
Wnt signalling can switch their fate. Specialised niches
defined by specific cell-cell/cell-matrix interactions in
the microenvironment together with soluble, ECM-bound
and microvesicle-associated host factors regulate CSC ac-
tivation [117]. Further research on such CSC niches, their
role in dormancy and the complex relationships between
CSCs and metastasis is essential [118-120].
Stromal changes predict early progression of disease
[121] and in-depth knowledge of how these conditionscan be manipulated for therapeutic benefit is required
[122]. Advances in the field of mechanotransduction are
shedding light on the mechanisms by which altered
matrix density or ‘stiffness’ can influence cell behaviour,
and enzymes such as lysyl oxidases (LOX) are potential
targets for therapy [123].
There is a need for better biomarkers of hypoxia in-
cluding gene expression profiles [124] serum proteins,
circulating tumour cells (CTCs) or functional imaging
that could be used non-invasively in patients to enable
more rigorous testing of its prognostic/predictive value. Al-
though hypoxia-targeted therapies have proven disappoint-
ing to date, new approaches are emerging. In common with
other targeted therapies for systemic disease, methods for
measuring efficacy will need to be redesigned [124-126].
Tumours have an increased dependence on aerobic
glycolysis. We need to understand how hypoxia affects
the tumour metabolome and thus may determine thera-
peutic responses [96]. The dependence of metabolically
adapted breast cancer cells on altered biochemical path-
ways presents new therapeutic targets linked to aerobic
glycolysis, acidosis and the hypoxic response [127,128].
Since these pathways also interact with classical survival
and proliferation signalling pathways via PKB/mTOR,
there are opportunities to develop new combinatorial
therapeutic strategies.
Breast cancer development and progression
Current status
Mammary stem cells There is increased understanding
of stem cell hierarchies and their potential roles in breast
development [129-131], but debate continues on the re-
lationship between normal stem and progenitor cells,
their dysregulation in cancer and the nature of putative
CSCs [132-135]. Most data suggest that breast CSCs are
a defined population with basal-like or mesenchymal-
like features [136-138]. There is emerging data from cell
line models that the CSC state is dynamic and can be in-
duced by the tumour microenvironment [110], and this
requires further investigation in human cancers. It is not
known whether there are differences in CSC phenotype
between breast cancer subtypes such as luminal vs.
TNBC [139,140]. An emerging consensus is that CSCs
initiate metastases and tumour regrowth after therapy,
but do not necessarily generate the majority cell popula-
tion in primary tumours.
Circulating tumour cells Blood-borne tumour cells are
routinely identified in breast cancer patients but their
scoring can depend upon the method used [141]. Their
relationship to disseminated tumour cells (DTCs) in tis-
sues is unclear, although a recent publication showed
that the presence of CD44+CD24-/lo cells (putative
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prognostic indicator in patients with early stage breast
cancer [142]. A population of CTCs from patients with
primary luminal cancer (expressing EPCAM, CD44,
CD47 and MET) generated multi-site metastases when
injected into mice. Hence it is likely that a subset of
CTCs have metastatic potential [143], which may equate
to CSCs. CTCs may occur in heterogeneous emboli of
multiple cell types; perhaps those containing stem-like
cells and/or ‘feeder’ cells are more likely to survive and
grow at distant sites.
Metastasis This key hallmark of breast cancer occurs
when cancer cells access lymphatic and vascular systems,
enabling dissemination via lymph nodes and then via the
venous and arterial vascular system to distant organs. Once
the disease has spread, it becomes life-threatening and
patients require systemic treatment. Metastatic relapse typ-
ically occurs many months to decades after surgery, thus
we need a greater understanding of the processes that
occur following tumour cell dissemination, including the
phenomenon of dormancy. Recent mathematical modelling
using relapse data has provided interesting insights and
proposals for hypothesis testing [144]. CTCs and DTCs that
generate metastases are, by definition, tumour-initiating
cells; hence their study needs to relate to CSC research
[145,146]. Since the last gap analysis, there has been a para-
digm shift in this area with the discovery of ‘pre-metastatic
niches’ (analogous to stem cell niches) in organs destined
to develop metastases [147,148].
In addition, seminal research using animal models has
identified tumour and host genes associated with metastatic
capacity (quite distinct from tumorigenic potential), and
also organotropism [149-151]. The relevance of these ex-
perimental observations to human breast cancer and the
translation of these findings into clinical studies require
confirmation but may provide additional predictive value
[152].
Reversible EMT, regulated by many factors including
transforming growth factor beta (TGFβ) signalling, Slug
and Snail transcription factors and hypoxia may be linked
to invasion, dissemination and drug resistance [153-156].
The role of EMT in human cancer metastasis is still con-
troversial and the underlying molecular mechanisms are
not fully understood [157]. However, mesenchymal/
stromal gene signatures have been identified which re-
late to TNBC subtypes, bone metastasis and resistance
to neoadjuvant therapies [158].
What are the key gaps in our knowledge and how might
these be filled?
Circulating tumour cells and nucleic acids It is un-
clear whether CTCs originate from primary tumours,micro-metastases or multiple primary and secondary
sites. Indeed, CTCs from distant metastases can poten-
tially reseed the primary tumour [159,160]. More re-
search is needed to define the origins of these cells.
Importantly, analysis of CTCs needs to be carried out as
far as possible in the clinical context, where their biology
can be correlated with patient outcomes. CTCs and
ctDNA are particularly useful where accessible breast
cancer material is not available, or to obtain serial sam-
ples during therapy, providing a window on response
and relapse.
To enable further progress, systems and protocols for
isolating and characterising CTCs need to be rigorously
defined and standardised, with an analysis of whether all
systems identify/isolate the same cells (or indeed all
CTCs, since EMT may preclude identification using epi-
thelial markers [141,161-163]). We need to know the
proportion of live, quiescent and apoptotic CTCs, their
characteristics and malignant potential and to under-
stand their relationship to the primary tumour and
whether different subsets of CTCs have different predict-
ive value.
The use of ctDNA is increasing as a potentially useful
further source of information on breast cancer biology
and response to therapy [164-166]. miRNAs identified in
the systemic circulation (free or exosome-associated)
[167] may also serve as diagnostic or prognostic bio-
markers and/or as therapeutic targets. Indeed, it has
been suggested that exosomes themselves, with their
emerging roles in bidirectional signalling, immune sup-
pression, subversion of targeted therapy and potentiation
of metastasis [168] could be removed (for example by
plasmapheresis) for therapeutic benefit [169].
Metastatic disease Metastasis is the major cause of
treatment failure, but it is far from clear why some pa-
tients with apparently similar disease succumb and not
others [170]. We need to identify key signalling path-
ways linked to organotropism [171] and to develop new
therapies for micro-and macro-metastatic disease [172].
Given the multiple breast cancer subtypes (and associ-
ated oncogenic drivers), it will be important to try to
align genotypes/epigenotypes to metastatic patterns, in
order to predict likely sites of relapse. Treatment deci-
sions are generally based on the profile of the primary
cancer, but information about the evolution of the dis-
ease from CTC, DTC or (where possible) metastases at
different sites is essential, since both gains and losses of
potential therapeutic targets have been observed in these
distinct tumour cell populations.
We need to understand how the host microenviron-
ment at secondary sites influences tumour cell survival
and to define similarities and differences between ‘per-
missive’ microenvironments in organs favoured by breast
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good deal since the last gap analysis about the ‘vicious
cycle’ of bone metastasis, whereby tumour cell interac-
tions within this unique microenvironment mutually
promote metastatic outgrowth and bone remodelling via
hormonal, immunological and inflammatory mediators.
These findings need to be translated into new therapies
targeting both tumour and host components [173] with
the paradigm extended to other specialised sites such as
brain [174].
Current therapies
Current status
Clinical therapies Current clinical therapies for breast
cancer are offered on an individual patient basis via a
multidisciplinary team and comprise surgery, radiother-
apy and drug therapies targeting oncogenic processes.
Selection of therapy is based on Level 1 evidence from
large RCTs or meta-analyses of such RCTs [175-177]. In-
creasingly, correlative translational studies are integrated
prospectively into clinical trials, aiming to define the op-
timal target population and provide insight into mecha-
nisms of resistance. The individualisation of treatment,
optimal duration of treatments, prediction of metastasis
or drug resistance remain challenging and reflect incom-
plete understanding of the underlying biology of breast
cancer. However, up-to-date guidelines are useful to de-
termine the best therapy for individual patients [178].
Immunohistochemical (IHC) analyses for selecting
therapeutic options generally lack reproducibility and
standardization resulting in poor concordance between
laboratories. The Quality Assurance programme for ER,
PR and human epidermal growth factor receptor 2
(HER2) in the UK has to some extent addressed this,
but for other biomarkers, including Ki67, there clearly
remain problems. We need to develop standardised pro-
tocols for better quantification of biomarkers [179], es-
pecially optimised methods of sample collection/storage
to ensure that unstable or transient biomarkers (such as
phosphoproteins or histone marks) are retained. This is
especially important for predictive markers such as
HER2, together with those which report on the efficacy
of HER2-directed therapies and other emerging targets.
Health inequalities remain in relation to treatment. Older
people diagnosed with cancer are more likely to experience
undertreatment, potentially having poorer clinical out-
comes than younger women for example [180,181]. In-
deed, there is a lack of data to inform decision making
about treatment for the elderly patient with breast cancer
in part attributable to their under-representation in trials,
but clinical teams may make inadvertent ageist decisions
[182,183]. In addition, breast cancer and its treatment can
have a considerable impact on women and their families[184]. Psychological distress is common, although not in-
evitable, and is associated with poorer quality of life
[185,186]. Regular distress screening is recommended as a
core component of good quality cancer care [187,188] in
order to provide appropriate support.
Surgery Surgery remains the primary treatment for most
women, with breast conservation (plus whole breast radio-
therapy) providing similar outcomes to mastectomy. Fol-
lowing mastectomy, breast reconstruction should be
considered, although uptake is incomplete. Axillary sur-
gery has moved from clearance via node sampling tech-
niques to sentinel node biopsy as the preferred means for
assessment of axillary metastasis in early breast cancer.
Neoadjuvant therapy, initially implemented to down-stage
inoperable cancers, is increasingly used to assess drug effi-
cacy in individuals and to reduce the extent of surgery re-
quired in good responders [189].
Radiotherapy Radiotherapy is both clinically effective
and cost-effective in the adjuvant and palliative settings.
The Oxford overview of adjuvant radiotherapy trials
[177] showed a halving of risk of first recurrence in all
risk groups and favourable effects of local control on
long-term survival. There is long-term confirmation of
the value of boost irradiation to the site of excision after
breast-conserving surgery in all subgroups, including
women >60 years [190]. The long-term safety and effi-
cacy of hypo-fractionated radiotherapy after breast-
conserving surgery and mastectomy for operable breast
cancer has recently been confirmed: (10-year results of
Canadian [191] and Standardisation of Breast Radiother-
apy (START) trials also suggesting generalisability to all
subgroups of patients [192,193].
Trials of partial breast irradiation evaluating intra-
operative radiotherapy in comparison to external beam
radiotherapy [194,195] or brachytherapy [196] have
short follow-up, but guidelines on partial breast irradi-
ation [197,198] have encouraged off-study use of partial
breast irradiation in advance of clinical trial results.
Omission of postoperative radiotherapy after breast-
conserving surgery in older, lower-risk women suggests
the differential in local recurrence rates may be accept-
able with a cumulative in breast recurrence of 2.5% in
breast conservation surgery alone vs. 0.7% for surgery
and postoperative radiotherapy (median follow-up 53
months age 55 to 75 years [199]) and at 10 years local
recurrence, nine for conservation alone vs. 2% for
surgery and radiotherapy in the =/>70 years, ER+ve
group [200].
Decision making Clinical decision-making tools to sup-
port individualised treatment can influence patients’ treat-
ment choices and experiences [201] and communication
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throughout the UK to improve the delivery of information
and support to patients [202]. A recent national survey of
over 40,000 patients with a broad range of cancers identi-
fied the fact that younger patients and ethnic minorities in
particular reported substantially less positive experiences
of involvement in decision making [203].
What are the key gaps in our knowledge and how might
they be filled?
Overtreatment A significant number of patients are
overtreated to achieve the improved survival overall in
early breast cancer, since we cannot define individual
risks of disease recurrence or sensitivity to treatment.
For survivors, the long-term side effects of treatment
may be significant; individualised treatment so that pa-
tients only receive the treatment they require to achieve
cure remains elusive. This is relevant to surgery, radio-
therapy, chemotherapy and endocrine therapy.
With the widespread adoption of sentinel node biopsy
(SNB)-limiting surgery to the axilla has substantially re-
duced arm morbidity [204]. A detailed understanding of
underlying tumour biology is required to support deci-
sions around surgical management, (for example axillary
node clearance or not after positive sentinel nodes). No
further axillary surgery even for one to two positive
nodes [205] and the equivalence of axillary clearance to
axillary radiotherapy for local disease recurrence (despite
the differing morbidities) in the presence of a low dis-
ease burden [206] demonstrate further progress in this
surgical setting. However, the optimal design of radiation
treatment fields for SNB-positive patients is not known.
For postoperative radiotherapy after breast-conserving
therapy, we do not have reliable ways of identifying low
risk, particularly in elderly patients for whom radiotherapy
might be omitted. While even low-risk patients have an
approximately 50% reduction in first recurrence [177], the
absolute gain for low-risk breast cancer patients (older
age, small, ER+ve cancers) after breast-conserving surgery
is very modest. We need reliable molecular markers of
identifying such low-risk groups or individuals.
Further work is required to clarify whether the re-
sponse to neoadjuvant chemotherapy can be used to
guide the selection of patients for regional nodal irradi-
ation [207] or whether patients who are clinically node
positive before neoadjuvant chemotherapy and are
converted to node negative after neoadjuvant chemo-
therapy on SNB require axillary nodal irradiation.
Individualisation of treatment Understanding the opti-
mal treatment strategies for an individual patient remains
elusive. A number of genomic (for example Mammaprint,
Oncotype Dx, PAM50) and immunohistochemical (forexample IHC 4) tests have been developed to predict
prognosis and latterly, response to chemotherapy; how-
ever, prospective trial evidence is still awaited [208]. Re-
cently, serum metabolite profiling using a combination
of nuclear magnetic resonance (NMR) spectroscopy and
liquid chromatography-mass spectrometry (LC-MS)
correctly identified 80% of breast cancer patients whose
tumours failed to respond adequately to chemotherapy,
showing promise for more personalized treatment proto-
cols [209].
Increased understanding of the dynamic changes that
occur over time is critical and will require repeated
assessment of tumour profiles. Genomic tests predict
response to endocrine or chemotherapy and those at
highest risk of relapse [210-212], but prospective trials
are required to determine whether axillary clearance or
chemotherapy can be avoided in node-positive patients.
Similarly, biological markers of radiosensitivity (tumour
and normal tissue) require better characterisation and
implementation into clinical strategies to allow personal-
isation of treatment and avoidance of late radiation-
induced toxicity [213].
CNS metastatic disease As a result of improved out-
come for patients with metastatic breast cancer (MBC),
central nervous system (CNS) metastatic disease is an
increasing therapeutic challenge [214]. Optimal treat-
ment strategies have yet to be defined including sequen-
cing or combination of stereotactic and whole brain
radiotherapy, systemic treatments, intrathecal treatment
approaches for leptomeningeal disease and prophylactic
interventions.
Bone metastatic disease Bisphosphonates reduce the
risk of developing breast cancer in osteoporotic and
osteopenic women by approximately 30% and the risk of
recurrence in early breast cancer when used at the time of
diagnosis [215,216].The interaction between the internal
endocrine environment and the effect of bisphosphonates
is complex and poorly understood. While negative results
overall were reported in the large UK AZURE trial [217]
women more than five years postmenopausal benefitted,
consistent with data from the NSABP-34 trial [218]. In
premenopausal women, bisphosphonates can abrogate the
bone loss associated with use of an AI. In addition, recur-
rence and death rates were reduced when used in combin-
ation with either tamoxifen or an AI after treatment with
the LHRH agonist goserelin (ABCSG12: [219]. Taken to-
gether, these studies suggest that a bisphosphonate may
have its greatest effect in a low-oestrogen environment.
The impact of bone-targeted therapy on extra-skeletal
metastases and locoregional relapse also highlights the
need to better understand experimental observations
concerning reseeding of tumours from dormant cells
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the role of RANK-RANKL signalling in mammary stem
cell biology allows for the possibility that targeting this
pathway with agents such as denosumab may offer a
prevention strategy for bone metastasis [221,222].Oligometastatic disease The role of localised treatment
of oligometastatic disease for example in the form of
selective stereotactic body radiotherapy, radiofrequency
ablation or surgery is currently unclear. The impact of ir-
radiating the primary tumour, biological communications
between treated primary site and distant metastases and
whether radiation therapy can convert the primary tumour
into an in situ vaccine [223] are relatively unexplored. Pro-
spective randomised trials are required, which should
ideally incorporate comprehensive molecular studies to
define subtypes most likely to respond; a related question
is how to treat primary breast cancer in patients present-
ing with metastatic disease.Radiotherapy The molecular basis of chemo-radiosensi-
tivity, biomarkers (including specific gene signatures,
proteomic markers) of tumour and/or normal tissue sensi-
tivity is required to allow selection of patients who may
benefit from adjuvant radiotherapy and avoid toxicity to
those who will not. Explanations for the mechanism(s) of
favourable impacts of locoregional control from radiother-
apy (RT) on survival are needed [224] and may include
in vivo real time biosensors of tumour biology to capture
transient changes in the tumour microenvironment that
drive metastasis.Hypofractionated adjuvant radiotherapy Even shorter-
dose fractionation schedules (that is one week of whole
breast radiotherapy) might achieve equivalent locoregional
control with comparable toxicity [225,226]. Partial breast
irradiation appears promising, but the long-term safety
and efficacy is still uncertain [197,198]. In addition, it ap-
pears likely that there is a subgroup of low-risk, older pa-
tients from whom postoperative radiotherapy can be
safely omitted [227,228]. The role of postmastectomy
radiotherapy in intermediate risk breast cancer [229], axil-
lary irradiation in sentinel node positive macro- or micro-
metastases [230] or boost dose in DCIS following breast-
conserving surgery [231] are all currently unclear. Further
definition of the role of stereotactic body radiotherapy, ac-
counting for tumour motion [232], in combination with
neoadjuvant systemic therapy, to liver or bone metastases
for oligometastatic disease are required. Similarly, the op-
timal dose fractionation for locally advanced disease needs
to be established [233].Molecularly targeted therapies
Current status
Anti-endocrine agents Multiple lines of clinical and
translational evidence have increased our knowledge of
the risk of recurrence, particularly for ER+ve disease
[212,234-236]. The optimal duration of treatment re-
mains incompletely defined but several RCTs have pro-
vided important new data: eight to ten years of adjuvant
treatment for ER+ve breast cancers is more effective
than five years of letrozole or tamoxifen [237-239].
Endocrine therapy resistance Comprehensive guide-
lines to define endocrine resistance have now been agreed
[240]. Clinical studies of various agents alone and in com-
bination with signalling inhibitors have been completed
since the last gap analysis. [241-243]. The biology of ERs,
including the importance of phosphorylation [244], ER co-
regulators [245], cross-talk with kinases [246] and altered
ER-binding events [247] nevertheless requires further elu-
cidation. MicroRNAs regulate ER activity and endocrine
responses, [248], while epigenetic events promote ER loss
or tumour suppressor silencing [249]. Cancer stem cells
may also be implicated in endocrine resistance [250].
The multiple cell-signalling changes driving resistance
and associated disease progression, nevertheless reveal po-
tential cancer cell vulnerabilities [251] for example mTOR
[72], EGFR/HER2 [252] and Src kinase [253]. New meth-
odologies such as large-scale siRNA screens have also pro-
vided novel therapeutic targets such as CDK10 and
fibroblast growth factor receptor 1(FGFR1) [254,255].
Oncogenic signalling inhibitors Several molecularly
targeted therapies have been licensed since the last gap
analysis including lapatinib and pertuzumab in HER2+
cancers [31] and the mTOR inhibitor everolimus in ER+ve
disease [72,256], which can overcome endocrine resistance
[257]. Agents targeting signal transduction pathways (not-
ably HER2) have had a significant impact in the treatment
of certain breast cancer subtypes [258]. However, there is
still limited understanding of the oncogenic pathways that
control the progression of premalignant breast diseases or
rare, but often aggressive, breast cancers (for example
metaplastic breast cancer) [259]. Molecules may have dis-
tinct functions in different cellular contexts, therefore
rigorous target validation is critical [260,261]; if a signal-
ling protein has a scaffold function, disruption of protein-
protein interactions may be required for efficacy. This re-
quires a detailed biophysical analysis of protein structures
and their key interactions.
For HER-2 positive disease, dual HER-receptor block-
ade is more effective than monotherapy and may help
prevent or overcome resistance [262,263]. Two years of
adjuvant trastuzumab offers no benefit over one year
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yet, unconfirmed [265]. In metastatic breast cancer,
serum metabolomic analyses may help to select patients
with HER2+ cancers with greater sensitivity to paclitaxel
plus lapatinib [266]. Multiple clinical trials are evaluating
PI3K pathway inhibitors; other new agents under devel-
opment include HSP90 inhibitors (for example NVP-
AUY922 and ganetespib); panHER, irreversible inhibi-
tors including neratinib and afatinib; monoclonal anti-
bodies directed against human epidermal growth factor
receptor 3 (HER3) and Src inhibitors such as saracatinib.
Resistance to signalling inhibitors Resistance to tar-
geted signal transduction agents is common, arising via
multiple mechanisms including utilisation of compen-
satory feedback loops or alternative signalling pathways.
Systems biology applications have begun to describe
these dynamic changes [267,268], and are critical to
identify key target points for effective therapeutic
intervention.
Robust guidelines (akin to REMARK) are not yet
employed in studies assessing the efficacy of novel ther-
apeutics. Such rigour is essential to ensure that both ap-
propriate models and quantitative outputs are fully utilised.
The best drug combinatorial approaches could then be de-
veloped based on mechanistic insight into opportunities
afforded by synthetic lethality [269,270]. More sophisticated
experimental models of DNA-damage response (DDR)
defects and those that accurately reflect mechanisms of
therapy resistance will enable the design of targeted thera-
pies to overcome these clinically relevant issues.
What are the key gaps in our knowledge and how might
they be filled?
Drug responses We lack a comprehensive understand-
ing of the exact mechanisms (both on- and off-target) by
which drugs exert anti-cancer effects in vivo; this is ex-
acerbated by our incomplete appreciation of networks,
cross-talk and redundancy in cell signalling. Given that
multiple inhibitors of specific pathways are now available
(for example PI3K/PKB/mTOR), harmonised approaches
to prioritisation of specific inhibitors/inhibitor classes
and of research objectives in clinical trials are required.
Clinical determinants of intrinsic and acquired resist-
ance There is incomplete understanding of the role of
diverse gene expression, epigenetic, protein and non-
coding RNA changes in the heterogeneous manifesta-
tions of clinical resistance, [271]. There is a lack of
equivalence between clinical, pathological, proliferative
and molecular resistance that needs to be addressed and
single genes or a canonical pathway are unlikely to be
responsible. Furthermore, multiple mechanisms havealso been implicated in acquired resistance, but their re-
lationship to intrinsic resistance remains to be defined.
Figure 5 illustrates the heterogeneity in patterns of gene
expression in clinical endocrine resistance, suggesting
that at least three major molecular mechanisms could be
involved [272].
There is a need to understand the clinical impact of
additional hormone receptors besides ERα, especially the
progesterone receptor (PR): whilst PR is prognostic, the
TEAM study has not demonstrated a predictive value
[273]. Similar considerations apply to ERβ [274,275] and
the androgen receptor (AR) [276], since trials of anti-
androgens are currently underway in metastatic breast
cancer [277].
It is not clear whether there are differences in ER+ve
premenopausal vs. postmenopausal endocrine resistance
[278]. As with other targeted therapies, the microenviron-
ment, therapy-induced signalling reprogramming and stem
cells are likely to play key roles. Proteomic profiling and
protein functionality are particularly poorly characterised
in the clinical resistance setting and such measurements
remain challenging but essential.
It is important to define the contribution of CSCs to
relapse on endocrine therapy, determine their sensitivity
to existing agents or identify the unique signalling path-
ways that sustain their clonogenic potential. Diagnostic
or prognostic tests based on ‘whole’ tumour samples
may fail to address these potentially significant minority
subpopulations of cells.
The few prospective studies to date have demonstrated
that changes in management for one in six patients could
be advised based on changes in breast cancer biomarkers
on relapse, particularly ER, PR and HER2 [279-281]. Con-
sequently, important clinical questions such as whether
changes in the frequency of drug administration or alter-
nating drug therapy could avoid or contribute to this
process need to be addressed. Considering host factors
such as adherence to medication [282], drug metabolism
[283] and immune mechanisms [284], alongside molecular
characteristics of tumours and the host microenvironment
is essential.Combinations and sequencing of targeted agents
with conventional agents Despite high-level evidence
for isolated treatment situations (for example adjuvant
treatment with AIs) [210,285,286], these have not been
integrated into sequential treatment strategies, for ex-
ample for adjuvant or first- or second-line palliative
treatment. As treatment standards change (with AIs as
standard adjuvant therapy), the sequence of tamoxifen as
adjuvant therapy with AIs for first-line metastatic ER+ve
disease may require adaptation. Such trials apply standard
treatments that manufacturers may have little interest in
12
8 
pr
ob
es
3 
se
le
ct
ed
 g
en
e 
cl
us
te
rs
60 endocrine resistant tumours
Stromal rearrangement
Interferon signalling
Oestrogen signalling
Unsupervised hierarchical clustering, mRNA data
Figure 5 Molecular heterogeneity of endocrine resistance. Unsupervised hierarchical clustering of mRNA from 60 endocrine-resistant breast
cancers shows heterogeneity in gene expression suggesting a multiplicity of underlying mechanisms including changes in oestrogen and
interferon signalling and stromal genes. Courtesy of Professor William Miller and Dr Alexey Larionov, based on a poster presentation at the thirty-
second annual CTRC-AACR San Antonio Breast Cancer Symposium, Dec 10–13, 2009 [272].
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to be explored.
Models are needed for the longitudinal study of hypoxic
‘microniches’ to inform timing of delivery of sequential
targeted therapies or chemotherapy with radiation; to test
real-time robotically controlled RT delivery to motion-
affected hypoxic regions of primary breast tumours; and
RT in combination with novel agents targeting pH regula-
tory mechanisms. Similarly, novel early-phase clinical tri-
als of preoperative RT + targeted therapy or neoadjuvant
hormonal therapy with baseline on-treatment biopsies for
markers and gene signatures of radiosensitivity (the window
of opportunity design) could complement the development
of trials of stereotactic body RT to primary + neoadjuvant
systemic therapy for limited-volume metastases in liver
and bone.
Practical considerations include the risk/benefit of
combining signalling inhibitors with anti-hormones, se-
quencing of tamoxifen and AIs [287] and targeting add-
itional steroidogenic enzymes [288]. Recent randomised
clinical studies have demonstrated substantial benefits
for combinations of targeted agents such as endocrine
therapy and mTOR inhibitors in ER+ve MBC [72] or
horizontal dual HER-receptor blockade [289-292]. This
results in several new challenges. Many patients benefit
from single agent endocrine therapy or HER2-blockadeand could avoid, at least initially, the toxicity of combin-
ation therapy if these cancers could be identified. There
is a clear need to identify patients who respond ad-
equately to targeted therapy (for example anti-HER-2
agents +/− endocrine agents) and do not need chemo-
therapy. Rational combinations need to be explored in
the appropriate setting, taking into consideration com-
pensatory induction of alternative signal transduction
pathways bypassing targeted treatments. Treatment ben-
efits in MBC or the neoadjuvant setting need converting
into a potential survival benefit in early breast cancer.
New therapeutic approaches Although phenotypically
similar to BRCA1 mutant breast cancers, TNBC are het-
erogeneous and lack of expression of ER, PR and HER2
is not a good predictor of homologous recombination
repair (HRR) status [293] Prognostic and predictive bio-
markers of response for TNBC are obvious gaps which
need to be addressed [294], complemented by an ex-
panded and representative panel of fully characterised
tumour cell lines and models [295]. More emphasis
should be directed at developing markers of drug resist-
ance and markers of resistance to current basal-like
breast cancer/TNBC therapies [296]. Better biomarker-
led characterisation could assist in patient stratification
and hopefully improved treatment responses. Similarly,
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types that fail to respond to existing therapies.
Lymphangiogenesis and angiogenesis Current under-
standing the role of lymphangiogenesis in metastasis
(and thus its potential as a therapeutic target akin to
neoangiogenesis) is limited [297]. In contrast, given the
morbidity associated with lymphoedema following ex-
tensive lymph node dissection, identifying a means of
inducing local regeneration of lymphatic vessels postop-
eratively could be envisaged. The contribution of the
lymphatic system to immune responses to tumours is
also underexplored [298]. Better in vitro and in vivo
models are required to understand the cellular and mo-
lecular complexities of pathological angiogenesis and
lymphangiogenesis, tumour cell intravasation, extrava-
sation, organ colonisation and strategies for effective
therapeutic interventions [299].
Anti-angiogenic therapies have been extensively trialled
but have not yet lived up to their promise, with
bevacizumab no longer approved for breast cancer by
the FDA [300-302]. Tumour vasculature is heteroge-
neous [303] and multiple, temporally dynamic mecha-
nisms contribute to the lack of durable responses [304].
The main focus has been vascular endothelial growth
factor (VEGF)-driven angiogenesis but there is consid-
erable redundancy in angiogenic signalling pathways
[305]. Also, there are no validated biomarkers of re-
sponse to anti-angiogenic therapies and it is likely that
the vasculature of anatomically dispersed metastases
will demonstrate further functional heterogeneity.
Exploiting the immune system Although generally
considered to be immunosuppressive, some chemothera-
peutic agents (and indeed monoclonal antibodies) may
involve an immune element; thus the combination of
immunotherapy and chemotherapy becomes a real pos-
sibility [306,307]. In node-positive, ER-/HER2- disease,
lymphocytic infiltration was associated with good prog-
nosis in the BIG 02–98 adjuvant phase III trial [284].
There needs to be a systematic quantification of immune
infiltration of breast cancer subtypes and how this re-
lates to tumour progression, response to therapy or
changes during treatment.
Cancer immunotherapy is gaining ground, whether
antibody-based or cell-based, with an increasing em-
phasis on targeting the tumour microenvironment (for
example macrophages or cancer-associated fibroblast
(CAFs)) with DNA vaccines [308]. In addition, several
immunogenic antigens (such as cancer testis antigens)
have been detected in poor-prognosis breast cancers,
which may serve as targets for therapy or chemopreven-
tion [309,310]. New strategies for enhancing natural im-
munity or eliminating suppressor functions are required.There is a need for better animal models for evaluating
immunotherapeutic strategies and in deciphering pos-
sible contributions to lack of responsiveness.
Living with and managing breast cancer and its
treatment
Current status
Survivorship Cancer and its treatment have a consider-
able and long-term impact on everyday life [311-313].
Consequences may be physical (for example pain, fa-
tigue, lymphoedema, hot flushes, night sweats and sex-
ual problems), or psychological (cognitive function,
anxiety, depression, fear of recurrence) and directly
affect relationships, social activities and work. The rela-
tionship between the cancer patient and his/her partner
will have a bearing on the level of distress: if communi-
cation is good, psychological distress will be lower [314].
Women may feel abandoned once treatment is com-
pleted with low confidence as a result [312,315]. The
current system does not meet their needs [184] and the
National Cancer Survivorship Initiative has been
established to investigate new models of aftercare.
A recent framework publication highlights the import-
ance of providing support to enable people to self-manage
their aftercare [315]. Patients benefit from improved sense
of control and ability to effect change together with an in-
creased likelihood of seeking health information [316,317].
Living with advanced breast cancer Quality of life in
women with metastatic breast cancer is poor [318] with
many experiencing uncontrolled symptoms [319]. Pain is
a significant problem throughout the illness, not just
with the end of life [318]. Depression, anxiety and trau-
matic stress also require intervention [320,321]. Those
with metastatic breast cancer receiving social support re-
port more satisfaction and a sense of fulfilment. Fewer
avoidance-coping strategies are associated with better so-
cial functioning and a larger social network. Social stress
has been found to increase pain and mood disturbance
and has been associated with isolation. In addition, self-
image and a decrease in sexual functioning challenge self-
esteem and relationships at a time when support is most
needed [322].
The impact of medical management on quality of life
and decision making regarding palliative chemotherapy
[323,324] and a lack of rehabilitation services [325,326]
has been recognised. The convergence of palliative treat-
ments and the end of life may impact on symptom con-
trol and care provision as well as place of death
[327,328].
Supportive interventions The main physical symptoms
associated with breast cancer treatment are fatigue, pain,
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and lymphoedema. Some interventions have demonstrated
benefit with specific side effects [329-331]. Meta-analysis
demonstrates that psychological interventions can reduce
distress and anxiety [332], provide some physiological bene-
fit, but with weak evidence regarding survival benefit [333].
Overall the evidence focuses on short-term benefit while
the longer-term implications are unknown.
Group interventions are less effective in reducing anx-
iety and depression than individualised interventions
such as cognitive behaviour therapy (CBT); [334], but do
result in social and emotional improvements [335] and
greater patient satisfaction [336]. Psycho-educational in-
terventions show improvements in physical and psycho-
social wellbeing [337] and reduced anxiety [338].
CBT reduces fatigue [339], insomnia [340] improves
physical activity and quality of life [341]. CBT appears to
be effective at all stages of breast cancer: group CBT can
significantly reduce the impact of menopausal symptoms
in breast cancer patients [342,343] with effects maintained
over six months. Care packages to help improve coping
skills, including group counselling sessions and/or
telephone-based prompts has shown supportive care in
the extended and permanent phases of survival to be ef-
fective [344]. Mindfulness-based stress reduction and cog-
nitive therapy can improve mood, endocrine-related quality
of life, and wellbeing at least in the short term [345].
Much evidence demonstrates the benefits of physical ac-
tivity for breast cancer patients [346]. RCTs show that
physical activity interventions during treatment show
small to moderate beneficial effects on cardiovascular fit-
ness, muscular strength and can reduce deconditioning.
Post treatment, physical activity interventions result in a
reduction in body fat and increase in fat-free mass, a mod-
erate to large effect on cardiovascular and muscular
strength, small to moderate effect on quality of life, fa-
tigue, anxiety and depression and some evidence of re-
duced lymphoedema and osteoporosis [347,348].
The translation of physical activity research into clin-
ical practice is a challenge. Currently, exercise-based
cancer rehabilitation is not routinely incorporated into
breast cancer care. However, from the National Cancer
Survivorship Initiative, Macmillan Cancer Support is
evaluating around 12 physical activity programmes and
evaluating physical, psychological and cost benefits. One
exercise intervention during therapy reassessed partici-
pants after five years and showed that those from the ex-
ercise group were still incorporating approximately 2.5
hours more physical activity a week and were more positive
than control patients [349]. Furthermore, other charities
are starting up similar programmes, such as Breast Cancer
Care’s ‘Best Foot Forward’. There are very few intervention
studies involving women with advanced metastatic cancer;
these predominantly focus on supportive-expressivetherapy and have been found to reduce distress [350] but
the benefits are not maintained in the long term [334].What are the key gaps in our knowledge and how might
they be filled?
Inadequate translation of research findings into prac-
tice While the problems are well recognised, there is in-
adequate clinical translation: for example, recognising
the benefits of physical activity requires incorporating
and testing intervention(s) in clinical practice. There is
also a lack of representation and sensitivity to the needs
of diverse groups. Similarly, the impact of breast cancer
goes beyond the patient; more attention should be paid
to their families, partners and children.
CBT is becoming integrated into clinical practice with
training for clinical nurse specialists but there is still a
need to consider how CBT and other interventions can
be better integrated to widen access. Novel interventions
must be developed and validated using methods based
upon sound theoretical principles, with demonstrable ef-
fectiveness (both clinical and financial) that can be
deployed as widely as possible to maximise benefit. A
clear understanding of the components of interventions
that promote uptake, adherence and long-term benefit is
required. Funding for research into living with and man-
aging the consequences of breast cancer and its treat-
ment is very limited, adversely impacting the building of
research capacity and expertise.
Establishing a multidisciplinary research consortium to
develop a theoretical framework to inform research ad-
dressing the needs of those living with and managing the
broad ranging consequences of breast cancer and its
treatment would inform choice of outcome measures,
innovative approaches to intervention design and testing.
Alternative trial designs to RCTs need to be considered
that incorporate patient preferences. It would also be of
great benefit to the field to draw up guidance on
implementing successful evidence into clinical practice.Survivorship Longitudinal studies are required to assess
the recovery of health and wellbeing and the long-term
adjustment of women and men who have a diagnosis of
breast cancer. This will allow investigation of how unmet
psychosocial needs and psychological morbidity during
diagnosis and treatment relate to quality of life, sexuality,
physical wellbeing and the effects of other illnesses later in
life. The long-term impacts of breast cancer and therapy
on everyday life need further investigation [351]. There are
implications for cardiac functioning, osteoporosis, neur-
opathy, cognitive dysfunction, lymphoedema and shoulder
mobility on the ability to maintain independence [352].
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epidemiological data on the problems of women who have
recurrence and metastatic disease. Research into integrated
oncology and palliative care models are needed to deter-
mine which approaches improve quality of life, psycho-
logical wellbeing, palliation of symptoms, treatment
decisions and end of life care. The needs of the families of
women with advanced metastatic cancer and how to sup-
port them and their carers most effectively are unclear.
Decision making at the end of life and the development of
tools to assist women and healthcare professionals to
choose appropriate treatment and place of death is needed.
Supportive interventions Specialist breast care nurses
have also been found to enhance the supportive care of
women with metastatic breast cancer. [353]. However, there
is a need to identify the active components of interventions
and an individual’s preference for different types of inter-
ventions to determine what works best for him or her.
Development of mindfulness and third-wave approaches
(for example Acceptance and Commitment Therapy) may
be effective. More RCTs of theory-based interventions for
treatment-related symptoms and innovative trial designs
are needed (with longer follow-up, analysis of moderators
and mediators and identified components) to support
women to manage their everyday lives. Interventions to
address specific psychological needs such as low self-
confidence and fear of recurrence also need to be tested.
Interventions are required to support women to increase
their physical activity, reduce the risk of recurrence and
examine the impact on late effects. The frequency, inten-
sity, type and timing of physical activity for maximum
benefit needs to be established. Effective means are re-
quired to support women to manage impaired sexuality/
sexual function, altered body image, lymphoedema, weight
gain [354], fear of recurrence, hormone therapy-related
symptoms [341,343,355,356], cognitive problems [357]
[358] and post-surgical problems [359,360]. Alternative
delivery of intervention needs to be explored, such as self-
management, telephone or online support and non-
specialist delivery: for example comparison of home-based
versus hospital-based interventions on physical activity
levels, patient satisfaction and motivation.
Strategic approaches to enable progress
Experimental models of breast cancer
Improved tissue culture models There is now a greater
appreciation of the importance of employing appropriate
human cancer cells. [361]. Commonly used breast cancer
cell lines are derived from metastases or pleural effusions
and fail to adequately represent the diversity and complex-
ity of breast cancer [362]. It has proven difficult to estab-
lish human tumour cell cultures representative of themajor subtypes and to maintain their genomic and pheno-
typic integrity. In addition, inter-patient variability and in-
advertent selection of the most malignant subtypes, skews
availability of representative material.
Better representation of breast cancer subtypes is re-
quired. Material from normal mammary tissue, premalig-
nant breast conditions, different ER+ve (and rare)
subtypes of breast cancers and ideally metastases from all
major sites are needed to cover the full spectrum of breast
cancer development and progression. Primary or minim-
ally passaged cell cultures will avoid issues of misidentifi-
cation, contamination or long-term culture artefacts.
Ideally, a central repository of well-annotated human pri-
mary breast cancer cells, associated host cells and cell lines
should be available to researchers linked to a searchable,
open-access database. Maintaining breast tumour tissue in
culture with its essential characteristics intact will enable
prognostic screening and testing of potential therapeutic
agents.
Reliable cell-type-specific markers are required and it
is also important to be able to recognise cancer stem cell
subpopulations (or transient phenotypes). Identification
of promoters for distinct cell subpopulations will en-
hance the number and scope of available in vitro models.
[363] and enable conditional genetic modifications for
mechanistic and target validation studies [364]. Ideally,
co-cultures (of both normal and precancerous breast
cells) with host cell populations such as fibroblasts,
myoepithelial cells, macrophages, adipocytes or vascular
endothelial cells are needed for studies of cellular inter-
actions within the appropriate ECM microenvironment.
Three-dimensional culture models can recapitulate the
tissue architecture of the breast and its characteristic inva-
sion patterns [89,365] especially if host stromal components
are incorporated [366]. Three-dimensional heterotypic
model systems are also enabling dissection of the effect
of cell-cell interactions and stromal elements in drug re-
sistance. Three-dimensional cultures require additional
refinement, higher throughput, quantitative assays [367]
and a move towards more physiologically relevant con-
ditions, for example by the use of bioreactors, enabling
long-term cultures under flow conditions; especially ap-
propriate for invasion assays [368,369].
Animal tumour models In the last five years there has
been an expansion in the use of orthotopic (anatomically
correct) breast cancer xenografts [370] and significant
advances in developing patient-derived xenografts (PDX)
[371]. These models better reflect the human cancers
from which they were derived and ER+ve tumours re-
spond appropriately to oestrogen ablation [372]. In-
creased use of genetically engineered mouse (GEM)
models driven by relevant abnormalities such as BRCA
mutations, HER2 overexpression and so on have enabled
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competent hosts and evaluation of new targeted therap-
ies such as PARP inhibitors and the emergence of
resistance [373]. Pros and cons of different models are
shown in Figure 6.
Expansion of PDX models will be required to cover all
the main breast cancer phenotypes [374] and to address
the contribution of ethnic diversity [375]. Advanced
GEM models with multiple genetic abnormalities, able
to generate both hormone sensitive and insensitive tu-
mours and in which metastasis occurs at clinically rele-
vant sites will also be a desirable refinement [376,377].
However, all such animal models will require validation
of any findings in the clinical setting [296,378,379].
Models are also required to investigate mechanisms of
the induction of (and escape from) long-term tumour
dormancy [380], a unique feature of breast cancer.• Standardised format
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Models for testing novel targeted agents against dis-
seminated disease Novel agents designed for systemic
administration are rarely tested against established in-
vasive/metastatic disease in preclinical animal models
[382,383]. There is an urgent need to develop better
models for the discovery and development of therapies
targeting metastases that are effective against all sites
of disease [384].
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Eccles et al. Breast Cancer Research 2013, 15:R92 Page 21 of 37
http://breast-cancer-research.com/content/15/5/R92dissemination has already occurred. In these cases, agents
targeting cell motility or invasion may have limited value.
It is therefore critical that preclinical models used for test-
ing such therapies incorporate established micrometastases
[385]. Similarly, there is a preponderance of lung metasta-
sis models in routine use. Other important sites of breast
cancer metastasis (for example bone, brain and, liver) are
relatively poorly represented, and this needs remedying in
preclinical drug evaluation [386-388]. Human tissue (such
as bone) transplanted into mice can provide a more rele-
vant microenvironment [389].
Preclinical or clinical trials focused on tumour shrinkage
are not appropriate for testing the efficacy of anti-invasive
or anti-metastatic agents that may reduce metastasis with-
out significantly impacting primary tumour growth [390].
Such approaches would likely fail current response evalu-
ation criteria in solid tumors (RECIST) criteria and show
little activity in the neoadjuvant setting or in late stage
patients with advanced metastatic disease. The potential
to utilise veterinary models for testing novel therapies
or RT-systemic therapy combinations and cross-disciplinary
collaboration with other scientific disciplines to develop
real-time in vivo biosensors of tumour biology offer novel
opportunities for significant progress.
Modelling drug resistance While challenging, estab-
lishing cell lines, tissue slice models and PDX from re-
lapsed and resistant cancers should be the ultimate goal
in order to provide a window on the mechanisms that
occur in patients where therapies fail. This would also
allow ex vivo targeting studies, employing signalling ana-
lyses and imaging systems to track resistance mecha-
nisms and progression.
Preclinical endocrine resistant models have largely
been derived from ER+ve MCF7 cells in vitro, either by
transfection of potential signalling molecules such as
HER2 or from continuous exposure to anti-endocrine
agents. Extensive panels of relapsed human tumour cell
lines are required to reflect the heterogeneity of clinical
resistant disease. This will allow assessment of the impact
of genetic background, duration, sequence and type of
endocrine agent (including AI) and rational evaluation of
agents to reverse resistance [391]. It is critical to validate
mechanisms identified in vitro with clinical resistance.
Longitudinal clinical samples and associated bio-
logical studies Biobanking has substantially improved
and is seen as a significant outcome of the last gap ana-
lysis [7] but the systematic analysis of clinical material
collected from serial tumour biopsies/ fine-needle aspir-
ation (FNA) (or ideally less invasive means such as ‘li-
quid biopsy’) before, during and following resistance
development is lacking. Procurement of matched mate-
rials remains challenging but is critical to establishingclinically relevant signalling mechanisms that culminate
in acquired resistance, allowing tracking of the dynamics
and prevalence of molecular events during response
through to any subsequent relapse. Care must be taken
to provide adequate sampling of inherently heteroge-
neous tumours in their primary, recurrent and dissemi-
nated settings, which may also provide material for
study of site-specific metastasis. [392] and samples must
be full annotated, ideally with ‘omics’ profiling and im-
munohistochemistry. The biopsy of metastatic lesions is
challenging and will require systematic introduction of a
‘warm autopsy’ programme [393]. A more realistic alter-
native is to further exploit the preoperative neoadjuvant
setting, despite the potential issues of heterogeneity and
sampling [394]. Collection of such samples is a particularly
valuable resource to address mechanisms of intrinsic re-
sistance and to track early therapy-associated signalling
changes (Figure 7).
Increased use of clinical relapse material will deter-
mine the relevance of preclinical findings and identify
potential candidates for detailed mechanistic evaluation
in appropriate tumour model systems. Ultimately the
goal is to determine if patients can be better stratified to
allow rational, personalised choices for further therapy.
This aspiration requires better integration between clini-
cians and scientists, trial providers and pharmaceutical
companies and would benefit from data sharing. Tissue-
based analyses from clinical trials need to be expanded
to incorporate all of the next generation sequencing
studies for research. These initiatives need to be co-
ordinated with cancer registry/ British Association of
Surgical Oncology (BASO) breast cancer data.
Blood samples for early diagnosis, monitoring treat-
ment response, early indicators of disease relapse (and
revealing increased heterogeneity) are imperative as our
ability to generate new biomarkers through emerging
technologies increases. These include detection of CTCs,
miRNAs, ctDNA, exosomes, and so on. Serum HER2
measurement may be another promising biomarker with
prognostic and predictive value [395-398].
Biomarkers of response or relapse With the exception
of ER and HER2, the availability of biomarkers to accur-
ately identify which patients will receive benefit from
targeted treatment, and indicators of patients at high risk
of progression or relapse remains limited. Further ad-
vances in molecularly targeted and anti-endocrine therapy
require clinically applicable predictive biomarkers to en-
able appropriate patient recruitment and to track re-
sponses to treatment [399,400]. These analyses should be
applied both to primary tumours and recurrent/metastatic
lesions to accommodate the profound heterogeneity
within individual cancers, which increases further during
disease progression. Understanding which molecular
Figure 7 Longitudinal sampling and enhanced biobanks. The longitudinal collection of blood and samples from normal breasts, primary
cancers and relapsed/metastatic/treatment-resistant disease is essential in order to address the origins, heterogeneity and evolution of breast
cancers. Samples are required from as broad a patient population as possible to understand ethnic, age-related and gender differences in
incidence, molecular subtypes, prognosis and response to treatment. Sequential samples (ideally patient-matched) from primary tumours and
metastases will enable detailed studies of tumour evolution/progression and provide material for generating new cell lines and patient-derived
xenografts for translational research. Multimodality imaging and metabolomic analyses will add further dimensions of valuable information. Based
on a figure provided courtesy of Professor William Gallagher, with thanks to Dr Rut Klinger (UCD Conway Institute).
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roles at different stages of disease will be key to designing
more effective targeted agents.
Validation of predictive markers for drug response
could be better facilitated by the routine inclusion of
such approaches into clinical trials rather than retro-
spective analyses of archived material. Any new bio-
markers should have well-defined cut-off points, be
thoroughly validated and robust. We require biomarkers
to identify patients who will not respond to trastuzumab
(primary resistance) in addition to the development of sec-
ondary acquired resistance. Discriminatory biomarkers are
required for combination therapies such as lapatinib and
trastuzumab in HER2-positive breast cancers. We lack
preclinical data that can predict which combination of
anti-HER2 therapies is optimal. There is also a need for
biomarkers that can identify patients who may be more
suitably treated with a tyrosine kinase inhibitor (TKI) ra-
ther than trastuzumab or combination anti-HER2 therapy.
New irreversible TKIs currently in clinical trials, (for ex-
ample afatinib and neratinib) have shown increased po-
tency in preclinical studies - could these now become the
mainstay for HER2-positive tumours?
Knowledge of the therapeutic benefits of mTOR inhib-
itors and of newer PI3K pathway inhibitors in breastcancer subtypes is rudimentary and we have no bio-
markers that can be used to optimise their therapeutic
index. In addition, knowledge of how important genomic
(for example PIK3CA mutations) and proteomic (for ex-
ample PTEN loss) biomarkers impact the efficacy of spe-
cific PI3K pathway inhibitors in the clinical setting is
limited. Further preclinical research on the functional
proteomic effects of genomic abnormalities in the PI3K
pathway in breast cancer is essential.
ER+ve tumour heterogeneity remains a challenge: lu-
minal A vs. luminal B subgroups impact on prognosis;
however, the mechanisms of endocrine failure remain
largely unknown. In ER+ve disease there is a lack of ac-
cepted biomarkers/signatures to distinguish endocrine-
sensitive patients from those with intrinsic insensitivity
or who will develop early or late resistance.
There is a need to develop non-invasive means of
detecting risk of subsequent relapse. In addition to
serial tumour samples, serum samples are warranted
as these may ultimately provide less invasive indicators
of acquisition of resistance. It remains unclear if
single or multiple biomarkers or transcriptional profiles
are optimal, or even if basic endocrinological markers
may prove valuable in the context of predicting
resistance.
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is routinely applied to the early detection and follow-up
of breast cancers, there is a need to increase the use of
functional screening techniques to better understand
tumour heterogeneity, identify features associated with
response or resistance to treatment and more rapidly
translate promising new preclinical methodologies to
clinical evaluation. It is important to evaluate emerging
imaging biomarkers of primary and metastatic breast
cancer and there is a requirement for new, more specific
and clinically translatable radiotracers for positron emis-
sion tomography/single-photon emission computed tom-
ography (PET/SPECT) [401,402]. We also need to identify
and assess the utility of imaging biomarkers associated
with other hallmarks of cancer beyond proliferation for
example invasion, altered metabolism, hypoxia. Attention
needs to be given as to how to validate novel imaging bio-
markers in adequately powered multi-centre clinical trials.
The funding available from most grant-awarding bodies
is insufficient to cover this, suggesting the need to con-
sider larger collaborative trials funded by more than one
agency.
Imaging may also be able to report on intratumoural
heterogeneity and identify the most significant region (for
example more aggressive/invasive areas via diffusion-
weighted magnetic resonance imaging (MRI)), to more
accurately direct biopsies or radiotherapy. EMT could be
addressed by the increased use of cluster, histogram and/
or texture analyses, but it will be necessary to define the
correct metrics to assess and quantify such phenotypes
[403]. It would be desirable to extend these techniques to
define different tumour subtypes such as DCIS, luminal or
TNBC non-invasively (which may identify mixed lesions
missed by homogenised or limited sample analyses) and
assess heterogeneity between metastases. Ideally, imaging
studies (both preclinical and clinical) should be co-
registered with linked genomic and proteomic information
in order to fully interpret the biological relevance of the
images obtained [404-406]. However, tissue collection is
often not co-ordinated with imaging studies and the added
benefit not always appreciated.
A key achievable goal is to non-invasively evaluate
predictive biomarkers of therapeutic responses. In-
creased adoption of more clinically relevant orthotopic
xenograft and transgenic murine models of primary
and metastatic breast cancer will demand robust pre-
clinical imaging approaches. The use of such models in
imaging-embedded trials of novel agents will improve
the accuracy of preclinical data, accelerating the devel-
opment of promising drugs, or enabling early closure of
suboptimal programmes. Such refined preclinical
trial designs will also prove highly informative in
establishing combination and/or sequential treatment
regimes.Clinical trial design and patient involvement Clinical
trial design should be adapted to use preoperative and
neoadjuvant models to allow novel therapies to be tested
in patients [394,407], identify de novo resistant cancers
and investigate how such resistance can be counteracted.
These approaches are particularly relevant for thera-
peutic strategies that target cancer stem cells, residual
(dormant) cancer cells or influence the tumour micro-
environment. Future trial design will also have to incorp-
orate dynamic strategies, such as using the response to
short-term treatment to guide the use of additional pre-
operative treatment. Given the increasing focus on small
target populations (for example molecular subtypes of
breast cancer), clinical trial strategies for effective patient
stratification or selection based on molecular character-
istics are required to allow routine integration into
large-scale clinical trials. In addition, the relatively long
period between surgery and relapse in breast cancer pa-
tients impacts negatively on the economic feasibility of
such clinical trials. New thinking will be required to
modify clinical trial design, and to consider biomarkers
that relate to invasive and metastatic phenotypes, for ex-
ample as in trials with denosumab where the develop-
ment of skeletal-related events (SRE) was an accepted
and measurable endpoint [221].
Patient reported outcomes There is a need to incorp-
orate standardised patient-reported outcome measures
(PROMs) both within clinical trials and in everyday clin-
ical practice. Currently, many trial reports are reliant on
the common terminology criteria for adverse events
(CTCAE) gradings about side effects, which show
alarming discrepancies with data actually collected from
patients [408].
Psychosocial considerations Further research is needed
to support the use of decision aids around surgery and
treatment and to define any benefits. There is also a
need for prospective research to identify consequences
of treatment and the impact of co-morbidities on the
lives of women with breast cancer so that future patients
can consider these as part of their decision making. The
experiences of minority ethnic groups, younger (<45
years) and older (>70 years) women in relation to their
treatment choices and management need further re-
search. Addressing non-adherence to endocrine therapy
and understanding the biological mechanisms of signifi-
cant side effects such as menopausal symptoms are poorly
understood. The value of incorporating lifestyle recom-
mendations as part of routine care and its impact on re-
covery and quality of life should be further explored.
Multidisciplinary collaborations and resources Increased
resources are required to support core (for example
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develop improved in vitro/in vivo/ex vivo model devel-
opment, serial clinical sample collection, advanced bio-
informatic/systems biology analysis, clinical biomarker
validation and ‘bench to bedside’ drug development.
Stronger multidisciplinary collaborations between la-
boratory scientists, clinicians, bioinformaticians and en-
gineers (and in turn with funding bodies and industry)
must be encouraged. Much better integration of com-
puter science, database engineering, data analytics and
visualisation, hardware and software engineering within
biological research will be essential to effectively read
and translate increasingly complex data. Convincing
drug companies of the benefits of a co-ordinated ap-
proach (tissue collection before, during and after treat-
ments) in clinical trials of new drugs is problematic, and
access of material for research purposes is limited.
Companies must be convinced of the benefits of accur-
ate biomarkers to allow for the better stratification of
patients. Even though this will limit their target popula-
tion, this should be offset by higher response rates and
faster regulatory approval.
Continued support is required for basic biological re-
search and understanding of cell signalling processes
with emphasis on interactions, cross-talk and microenvi-
ronmental regulation. It is important that approaches in
this area are linked to systematic investigations and pre-
cise analyses of cell responses to a wide range (and com-
bination) of inhibitors, tested in clinically relevant breast
cancer model systems. A key element is open discussion
and learning from negative results to avoid unnecessary
duplication of research. Sharing of information, best
practice, optimised model systems, technologies and re-
sources is essential, perhaps through developing web-
based analysis portals. Such approaches are needed to
integrate and interpret diverse sources of data to under-
stand the plasticity of signalling emerging during treat-
ment though to resistance (Figure 8).
A co-operative network of advanced radiotherapy facil-
ities, analogous to the Experimental Cancer Medicine
Centres is needed to ensure adequate patient numbers
for clinical trials. Engaging patients and healthcare teams
is critical to enable complex biological studies (especially
longitudinal biomarker studies). Lack of academic clini-
cians (particularly in radiation oncology), radiobiology
and physics staff nationally and rising service pressures
on NHS staff are all detrimental to delivery of clinical
translational research.
Conclusions
While substantial advances have been made in breast
cancer research and treatment in the last five years,
there remain significant gaps in translating this newly
acquired knowledge into clinical improvements.Understanding the specific functions and contextual
interactions of genetic and epigenetic advances and
applying this knowledge to clinical practice, including
tailored screening, will require deeper understanding of
molecular mechanisms and prospective clinical valid-
ation. Even with clinically actionable tests, decision
making, support for patients and their families and
overcoming the barriers to lifestyle change (diet, exer-
cise and weight) alongside chemopreventive strategies
are required to optimise health outcomes.
Genomic profiling of sequential clinical samples (pri-
mary, relapsed and secondary cancers, CTC, ctDNA, be-
fore, during and following therapy) is required to identify
specific biomarkers of inter-/intra-tumour spatial and
temporal heterogeneity, metastatic potential, sensitivity to
radiotherapy and different forms of chemotherapy, de
novo or acquired resistance. This will significantly improve
patient stratification for existing therapies and identify key
nodes in these dynamic processes as potential new thera-
peutic targets. Validated markers of these processes (in-
cluding minimally invasive multimodality imaging and
metabolomics methodologies) will benefit from synergies
between laboratory and clinical interactions. Improved un-
derstanding of the interactions, duration, sequencing and
optimal combinations of therapy should allow better
stratification of patients and reduce overtreatment (or
undertreatment) enhancing prevention or survival while
reducing morbidity.
Further genetic, epigenetic and molecular profiling of
breast cancers and their associated stroma would be sig-
nificantly enhanced by expanded panels of cell lines
representing all major breast cancer subtypes and three-
dimensional tumour-host heterotypic co-culture systems.
This would enable increased understanding of the molecu-
lar drivers behind specific cancer subtypes and their role
(together with microenvironmental modifiers) in treatment
resistance and metastasis. Deciphering tumour-stromal in-
teractions incorporating metabolic and immunological host
mechanisms and intracellular/extracellular signalling path-
ways would have therapeutic implications for prevention
and therapy. Advanced high-content analytical methods
will enable consideration of additional key cancer ‘hall-
marks’ beyond proliferation (for example cell motility
and invasion) and enable screening for inhibitors under
more physiologically relevant conditions. Better preclin-
ical animal models (for example genetically engineered
mice expressing relevant human oncogenes, which develop
widespread metastases; patient-derived xenografts) are re-
quired. Such models would enable testing of hypotheses
derived from clinical observations and rigorous target val-
idation and evaluation of novel therapies in the metastatic
setting (and where desirable in immunocompetent hosts).
Underpinning these advances, optimised multimodality
imaging for diagnosis and therapeutic monitoring should
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Figure 8 Integrated vision of multidisciplinary research. Enhanced integration and utilisation of the vast amount of clinical and experimental
observations relating to breast cancer is urgently required. Clinical observations generate hypotheses relating to the origins of cancer, its
underlying molecular pathology and potential vulnerabilities that could be exploited for therapeutic benefit. Such insights provide opportunities
for testing and validation in in vitro, in vivo and in silico models. Drug discovery aims to provide inhibitors of major oncogenic ‘drivers’ for use
singly or in combination with conventional therapies; such personalised medicine requires the co-development of predictive and
pharmacodynamic biomarkers of response. Results from preclinical therapy studies and clinical trials should be fed back into searchable databases
to reveal reasons for treatment failure and allow new strategies to be tested and deployed. Based on a figure provided courtesy of Professor
William Gallagher, with thanks to Professor Walter Kolch (UCD Conway Institute).
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Clinically annotated tissues for translational research must
be linked to bioinformatics as key contributors to interdis-
ciplinary research, essential for rapid future advances. In-
creasing numbers of women and men are surviving breast
cancer. Alongside advances in understanding the disease
and using that knowledge for prevention, earlier detection
and successful treatment of breast cancer, interventions to
improve the survivorship experience require innovative ap-
proaches to address the consequences of diagnosis and
treatment.
Top 10 gaps:
1. Understanding the specific functions and contextual
interactions of genetic and epigenetic changes in the
normal breast and the development of cancer
2. Effective and sustainable lifestyle changes (diet, exercise
and weight) alongside chemopreventive strategies3. Tailored screening approaches including clinically
actionable tests
4. Molecular drivers behind breast cancer subtypes,
treatment resistance and metastasis
5. Mechanisms of tumour heterogeneity, tumour
dormancy, de novo or acquired resistance; how to
target the key nodes in these dynamic processes
6. Validated markers of chemosensitivity and
radiosensitivity
7. Interactions, duration, sequencing and optimal
combinations of therapy for improved
individualisation of treatment
8. Optimised multimodality imaging for diagnosis and
therapeutic monitoring should enable better
evaluation of primary and metastatic disease
9. Interventions and support to improve the
survivorship experience including physical
symptoms such as hot flushes and lymphoedema
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research including tumour, non-tumour and blood
based materials from primary cancers, relapsed and
metastatic disease
Proposed strategic solutions:
For significant progress to be made in treating and
supporting those impacted by breast cancer (and ultim-
ately preventing and overcoming this disease) basic and
translational research scientists in academia and indus-
try, funding bodies, government and patients need to
work together to achieve the following key strategic
solutions.
1. To reverse the decline in resources targeted towards
breast cancer research, funding must be increased
and strategically directed to enhance our current
knowledge, develop the talent pool, and apply
evidence-based findings to improve clinical care
2. A fully cohesive and collaborative infrastructure
must be developed to support breast cancer
research; this requires improved access to
appropriate, well-annotated clinical material
including longitudinal sample collection with expert
bioinformatics support and data sharing.
3. Building on sound investment and infrastructure, all
stakeholders (researchers, funders, government,
industry and patients) must work together on the
clinical development and translation of research
knowledge to patient benefit. For example,
enhanced, clinically relevant, in vitro and in vivo
models are required for evaluation of new therapies
together with validated biomarkers, which should
then be embedded in clinical practice.
4. Research funders, government and industry should
provide innovative programmes to encourage
collaborative cross-disciplinary working practices,
including the training of more physician-scientists
and integration of physical sciences, technology and
engineering.
5. Improving clinical trial methodologies, including
patient involvement, recognising that a changing
global environment is required to ensure that all
clinical developments can be tested and ultimately
implemented for patient benefit.
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